NCT06207045

Brief Summary

The goal of this open-label randomized controlled trial is to explore the benefit of limb elevation in inpatient gout flare episodes, compared with standard treatment The main questions are;

  • Is limb elevation able to reduce pain during gout flare episodes to a greater degree compared with standard treatment ?
  • Is Is limb elevation able to reduce joint swelling during gout flare episodes to a greater degree compared with standard treatment ? Participants will be divided into 2 group;
  • Limb elevation group
  • control group All participants will receive standard medical therapy consisting of colchicine 0.6 mg per day plus prednisolone 30 mg per day for 2 days

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Feb 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 5, 2024

Completed
11 days until next milestone

First Posted

Study publicly available on registry

January 16, 2024

Completed
16 days until next milestone

Study Start

First participant enrolled

February 1, 2024

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2024

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2024

Completed
Last Updated

January 16, 2024

Status Verified

January 1, 2024

Enrollment Period

4 months

First QC Date

January 5, 2024

Last Update Submit

January 5, 2024

Conditions

Keywords

Gout, arthritis, gout flare

Outcome Measures

Primary Outcomes (1)

  • Reduction of pain score

    10-points Visual Analogue Scale

    48 hours

Secondary Outcomes (1)

  • Joint circumference

    48 hours

Study Arms (2)

limb elevation group

EXPERIMENTAL

limb elevation plus standard medication

Procedure: limb elevation

control group

NO INTERVENTION

standard medication only

Interventions

limb elevation more than 45 degrees

limb elevation group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged ≥ 18 years
  • Diagnosis of Gout according to 2015 The ACR/EULAR gout classification criteria

You may not qualify if:

  • Receive Non-Steroidal Anti-inflammatory Drugs or Intra-articular corticosteroids or prednisolone \> 10 mg within 24 hours before enrollment
  • Unstable vital sign
  • Receiving joint aspiration for release joint effusion ≥ 10 ml after enrollment
  • Gout flares involve axial joints e.g. hip
  • Glomerular Filtration Rates \< 30 ml/min/1.73m2
  • Communication problems

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Thammasat University

Pathum Thani, 12120, Thailand

Location

MeSH Terms

Conditions

GoutArthritis

Condition Hierarchy (Ancestors)

Joint DiseasesMusculoskeletal DiseasesCrystal ArthropathiesRheumatic DiseasesPurine-Pyrimidine Metabolism, Inborn ErrorsMetabolism, Inborn ErrorsGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • saitip sangkamanovet

    Thammasat University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

RatchayaSaitip Lertnawapan

CONTACT

kanon jatuworapruk

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr.

Study Record Dates

First Submitted

January 5, 2024

First Posted

January 16, 2024

Study Start

February 1, 2024

Primary Completion

May 31, 2024

Study Completion

October 31, 2024

Last Updated

January 16, 2024

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will not share

Locations